Do you offer neoadjuvant chemotherapy to nested variant urothelial carcinoma (NVUC) of the bladder?

Community
Company
News
Contact Us
Sign in

Topics: Genitourinary Cancers • Bladder Cancer • Medical Oncology

Assume a case where NVUC is the majority/pure variant, rather than just a focus of variant disease in UC background. Data seem to suggest response to NAC may be poor?

Related Questions

Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?

Based on the VESPER trial data, do you recommend the full 6 cycles or 3-4 cycles of ddMVAC for neoadjuvant muscle invasive bladder cancer treatment?

Would you offer neoadjuvant chemotherapy to high grade T1 urothelial carcinoma in a bladder diverticulum?

For patients with T1 bladder cancer who have severe obstructive uropathy/hydronephrosis, do you treat as high risk stage I disease with RC, or clinically upstage and manage as a more locally advanced disease (NAC+RC)?

How would you manage metastatic small cell bladder cancer in a patient who is platinum ineligible?

Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?

Is there a role for single agent immunotherapy in a patient with T2 muscle-invasive bladder cancer without lymph nodes or distant metastasis who declines chemotherapy and cystectomy?

Given results of BCON trial, do you add carbogen and nicotinamide for patients receiving definitive radiotherapy for bladder cancer, particularly for non-cisplatin eligible candidates?

Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?

Would you offer neoadjuvant chemotherapy prior to trimodality therapy in a fit patient who refuses surgery for muscle-invasive bladder cancer?